Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease–Associated Interstitial Lung Disease-Reference-Cited by-同舟云学术

Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease–Associated Interstitial Lung Disease

Published:2020-12-04 Issue:1 Volume:3 Page:3-7
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheuma

Author:

Zhu Lisa¹^ORCID,Chung Melody P.¹^ORCID,Gagne Laurence²,Guo Haiwei H.¹^ORCID,Guenther Zachary³,Li Shufeng¹,Jacobs Susan¹,Morisset Julie²,Mooney Joshua J.¹^ORCID,Raj Rishi¹,Chung Lorinda¹^ORCID

Affiliation:

1. Stanford University Stanford California United States

2. Centre Hospitalier de l’Universite de Montreal Montreal Quebec Canada

3. University of Calgary Calgary Alberta Canada

Funder

Scleroderma Research Foundation

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11210

Reference12 articles.

1. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

2. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

3. Progressive lung fibrosis with patients with systemic sclerosis‐associated interstitial lung disease in the EUSTAR database [abstract];Hoffmann‐Vold AM;Arthritis Rheumatol,2018

4. Glucocorticoids in systemic sclerosis: weighing up the benefits and risks ‐ a systematic review;Iudici M;Clin Exp Rheumatol,2013

5. B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Rituximab Versus Cyclophosphamide and Mycophenolate for the Treatment of Interstitial Lung Disease in Systemic Sclerosis: A Systematic Review;Cureus;2024-08-31

2. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial;European Respiratory Journal;2023-05-25

3. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion;Frontiers in Medicine;2022-06-30

4. Immunomodulatory treatment of interstitial lung disease;Therapeutic Advances in Respiratory Disease;2022-01

5. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases;Expert Opinion on Drug Safety;2021-09-01